Low-dose Brachytherapy Seen as Viable Choice for Lower Risk Patients, Long-term Study Finds

Low-dose Brachytherapy Seen as Viable Choice for Lower Risk Patients, Long-term Study Finds
Patients with low-to-intermediate prostate cancer who receive low-dose permanent brachytherapy, a type of radiation therapy, have excellent outcomes in the long run, according to data recently presented at the American Society for Radiation Oncology (ASTRO) 2017 Annual Conference in San Diego, California. At nine years of follow-up, only a minority — 11-14 percent — of patients treated with either Iodine-125 (I-125) or Cesium-131 (Cs-131) brachytherapy had seen their cancer return, as assessed by a rise in PSA levels. The poster, "Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate Brachytherapy Trial," was presented at the conference by Brian Moran, medical director of the Prostate Cancer Foundation of Chicago in Westmont, Illinois. Brachytherapy is a relatively new cancer treatment that implants small radioactive seeds directly into a patient's tumor. This ensured that radiation is be delivered specifically to a cancer site while sparing healthy surrounding tissues. The seeds used in brachytherapy may be composed of diverse radioactive compounds. Cesium-131 seeds, in particular, have unique attributes that are seen shorten treatment time and reduce common prostate side effects. Results published in The International Journal of Radiation Oncology, Biology and Physics in August 2017 showed that
Subscribe or to access all post and page content.